Andrew Cheng is President and CEO of Akero Therapeutics, Inc.. Currently has a direct ownership of 605,417 shares of AKRO, which is worth approximately $19.2 Million. The most recent transaction as insider was on Dec 31, 2020, when has been sold 3,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 605K
0.29% 3M change
31.33% 12M change
Total Value Held $19.2 Million

Andrew Cheng Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 31 2020
SELL
Bona fide gift
-
3,000 Reduced 0.83%
359,989 Common Stock
Dec 28 2020
BUY
Exercise of conversion of derivative security
$4,638 $0.62 p/Share
7,480 Added 2.13%
342,989 Common Stock
Dec 21 2020
BUY
Exercise of conversion of derivative security
$6,510 $0.62 p/Share
10,500 Added 3.03%
335,509 Common Stock
Dec 15 2020
SELL
Bona fide gift
-
2,500 Reduced 0.76%
325,009 Common Stock
Dec 11 2020
SELL
Bona fide gift
-
50 Reduced 0.02%
327,509 Common Stock
Jun 30 2020
BUY
Grant, award, or other acquisition
$21,252 $17.07 p/Share
1,245 Added 0.38%
327,559 Common Stock

Also insider at

VERA
Vera Therapeutics, Inc. Healthcare
ABUS
Arbutus Biopharma Corp Healthcare
AC

Andrew Cheng

President and CEO
South San Francisco, CA

Track Institutional and Insider Activities on AKRO

Follow Akero Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO